Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free LABS Stock Alerts

MediPharm Labs (LABS) Competitors

MediPharm Labs logo
C$0.08 0.00 (0.00%)
As of 05/25/2026 03:59 PM Eastern
Compare

LABS vs. MDP, CWEB, TGOD, NINE, and DB

Should you buy MediPharm Labs stock or one of its competitors? MarketBeat compares MediPharm Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediPharm Labs include Medexus Pharmaceuticals (MDP), Charlotte's Web (CWEB), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), and Decibel Cannabis (DB). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does MediPharm Labs compare to Medexus Pharmaceuticals?

Medexus Pharmaceuticals (TSE:MDP) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Medexus Pharmaceuticals has a beta of 0.5717, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, MediPharm Labs has a beta of -0.448907, suggesting that its stock price is 145% less volatile than the broader market.

Medexus Pharmaceuticals has a net margin of -0.27% compared to MediPharm Labs' net margin of -20.21%. Medexus Pharmaceuticals' return on equity of -0.52% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Medexus Pharmaceuticals-0.27% -0.52% 4.89%
MediPharm Labs -20.21%-23.55%-7.17%

3.1% of Medexus Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of MediPharm Labs shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of MediPharm Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MediPharm Labs had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 1 mentions for MediPharm Labs and 0 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Medexus Pharmaceuticals Neutral
MediPharm Labs Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medexus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
MediPharm Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Medexus Pharmaceuticals has higher revenue and earnings than MediPharm Labs. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$99.43M1.32C$3.26M-C$0.02N/A
MediPharm LabsC$45.12M0.75-C$12.05M-C$0.02N/A

Summary

Medexus Pharmaceuticals beats MediPharm Labs on 11 of the 13 factors compared between the two stocks.

How does MediPharm Labs compare to Charlotte's Web?

MediPharm Labs (TSE:LABS) and Charlotte's Web (TSE:CWEB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

MediPharm Labs has a net margin of -20.21% compared to Charlotte's Web's net margin of -74.93%. MediPharm Labs' return on equity of -23.55% beat Charlotte's Web's return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-20.21% -23.55% -7.17%
Charlotte's Web -74.93%-2,056.41%-17.25%

MediPharm Labs has a beta of -0.448907, meaning that its share price is 145% less volatile than the broader market. Comparatively, Charlotte's Web has a beta of 1.718843, meaning that its share price is 72% more volatile than the broader market.

In the previous week, MediPharm Labs had 1 more articles in the media than Charlotte's Web. MarketBeat recorded 1 mentions for MediPharm Labs and 0 mentions for Charlotte's Web. MediPharm Labs' average media sentiment score of 0.00 equaled Charlotte's Web'saverage media sentiment score.

Company Overall Sentiment
MediPharm Labs Neutral
Charlotte's Web Neutral

0.3% of MediPharm Labs shares are held by institutional investors. Comparatively, 2.6% of Charlotte's Web shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Comparatively, 11.3% of Charlotte's Web shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MediPharm Labs has higher earnings, but lower revenue than Charlotte's Web. MediPharm Labs is trading at a lower price-to-earnings ratio than Charlotte's Web, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$45.12M0.75-C$12.05M-C$0.02N/A
Charlotte's WebC$48.79M1.91-C$25.55M-C$0.23N/A

Summary

MediPharm Labs and Charlotte's Web tied by winning 6 of the 12 factors compared between the two stocks.

How does MediPharm Labs compare to Green Organic Dutchman?

MediPharm Labs (TSE:LABS) and Green Organic Dutchman (TSE:TGOD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

0.3% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Green Organic Dutchman has a net margin of 0.00% compared to MediPharm Labs' net margin of -20.21%. Green Organic Dutchman's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-20.21% -23.55% -7.17%
Green Organic Dutchman N/A N/A N/A

MediPharm Labs has higher revenue and earnings than Green Organic Dutchman. MediPharm Labs is trading at a lower price-to-earnings ratio than Green Organic Dutchman, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$45.12M0.75-C$12.05M-C$0.02N/A
Green Organic DutchmanC$31.37M0.00-C$137.58M-C$0.26N/A

In the previous week, MediPharm Labs had 1 more articles in the media than Green Organic Dutchman. MarketBeat recorded 1 mentions for MediPharm Labs and 0 mentions for Green Organic Dutchman. MediPharm Labs' average media sentiment score of 0.00 equaled Green Organic Dutchman'saverage media sentiment score.

Company Overall Sentiment
MediPharm Labs Neutral
Green Organic Dutchman Neutral

Summary

MediPharm Labs beats Green Organic Dutchman on 6 of the 10 factors compared between the two stocks.

How does MediPharm Labs compare to Delta 9 Cannabis?

Delta 9 Cannabis (CVE:NINE) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Delta 9 Cannabis has higher earnings, but lower revenue than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$12.87M6.94C$4.69MC$0.0519.07
MediPharm LabsC$45.12M0.75-C$12.05M-C$0.02N/A

Delta 9 Cannabis has a net margin of 0.00% compared to MediPharm Labs' net margin of -20.21%. Delta 9 Cannabis' return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Delta 9 CannabisN/A N/A N/A
MediPharm Labs -20.21%-23.55%-7.17%

In the previous week, MediPharm Labs had 1 more articles in the media than Delta 9 Cannabis. MarketBeat recorded 1 mentions for MediPharm Labs and 0 mentions for Delta 9 Cannabis. Delta 9 Cannabis' average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Delta 9 Cannabis Neutral
MediPharm Labs Neutral

0.3% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Delta 9 Cannabis beats MediPharm Labs on 7 of the 11 factors compared between the two stocks.

How does MediPharm Labs compare to Decibel Cannabis?

Decibel Cannabis (CVE:DB) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

0.7% of Decibel Cannabis shares are owned by institutional investors. Comparatively, 0.3% of MediPharm Labs shares are owned by institutional investors. 1.1% of Decibel Cannabis shares are owned by company insiders. Comparatively, 4.5% of MediPharm Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Decibel Cannabis presently has a consensus price target of C$0.18, suggesting a potential upside of 40.00%. Given Decibel Cannabis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Decibel Cannabis is more favorable than MediPharm Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Decibel Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
MediPharm Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Decibel Cannabis had 2 more articles in the media than MediPharm Labs. MarketBeat recorded 3 mentions for Decibel Cannabis and 1 mentions for MediPharm Labs. Decibel Cannabis' average media sentiment score of 1.21 beat MediPharm Labs' score of 0.00 indicating that Decibel Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Decibel Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MediPharm Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Decibel Cannabis has a net margin of -3.78% compared to MediPharm Labs' net margin of -20.21%. Decibel Cannabis' return on equity of -1.05% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Decibel Cannabis-3.78% -1.05% 3.04%
MediPharm Labs -20.21%-23.55%-7.17%

Decibel Cannabis has higher revenue and earnings than MediPharm Labs. Decibel Cannabis is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel CannabisC$121.32M0.59-C$1.03M-C$0.01N/A
MediPharm LabsC$45.12M0.75-C$12.05M-C$0.02N/A

Decibel Cannabis has a beta of 0.067304, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, MediPharm Labs has a beta of -0.448907, suggesting that its stock price is 145% less volatile than the broader market.

Summary

Decibel Cannabis beats MediPharm Labs on 14 of the 17 factors compared between the two stocks.

Get MediPharm Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABS vs. The Competition

Export
MetricMediPharm LabsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$33.99MC$2.25BC$6.46BC$12.16B
Dividend YieldN/A2.95%2.76%6.20%
P/E Ratio-4.005.1621.2137.64
Price / Sales0.751,770.59554.3811.68
Price / Cash1.3010.1843.4982.29
Price / Book0.9710.6110.374.50
Net Income-C$12.05MC$20.70BC$3.57BC$299.09M
7 Day PerformanceN/A8.21%6.40%2.48%
1 Month PerformanceN/A3.75%3.53%1.47%
1 Year PerformanceN/A22.83%34.04%53.55%

MediPharm Labs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABS
MediPharm Labs
N/AC$0.08
flat		N/A+6.7%C$33.99MC$45.12MN/A130
MDP
Medexus Pharmaceuticals
N/AC$4.01
-1.0%		N/A+47.3%C$130.82MC$99.43MN/A98
CWEB
Charlotte's Web
N/AC$0.59
-3.3%		N/A+346.2%C$94.72MC$49.90MN/A164
TGOD
Green Organic Dutchman
N/AN/AN/AN/AC$89.95MC$31.37MN/A41
NINE
Delta 9 Cannabis
N/AC$1.03
+3.0%		N/A+0.0%C$89.36MC$12.87M19.07940

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:LABS) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel